BiotechTube
iosBio Pharma

iosBio Pharma

Oxford, United Kingdom· Est.
iosbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

iosBio Pharma is a private, pre-clinical stage biotech developing next-generation oral vaccines. Its core innovation is the OraPro™ platform, which enables needle-free, thermostable oral delivery, potentially eliminating cold-chain logistics and enabling global vaccine access. The company's lead candidate, OraPro-EBV, is preparing for Phase 1 trials, targeting EBV-associated diseases like multiple sclerosis and certain cancers. iosBio is currently seeking £12-30 million in funding to advance its lead program into clinical development.

Infectious Disease

Technology Platform

OraPro™ (thermostable oral delivery platform), Enhanced Surface Display (ESD™) (antigen presentation technology), and AI-Assisted Antigen Design.

Opportunities

The global need for an EBV vaccine is a massive, untapped market linked to MS and cancer.
The OraPro platform's thermostability and oral administration address critical barriers in global vaccine distribution and compliance, opening opportunities in low-resource settings and for broader disease targets.

Risk Factors

High risk of clinical failure as the oral vaccine platform transitions from preclinical to human trials.
The company is dependent on raising significant capital (£12-30m) to reach its next milestone, and faces potential competition from other EBV vaccine developers using more traditional, injectable approaches.

Competitive Landscape

The oral, thermostable vaccine space is nascent but competitive, with companies like Vaxart (oral tablet vaccines) also active. For EBV specifically, competitors include Moderna (mRNA injectable in Phase 1) and the NIH, making speed to clinic and proof of superior mucosal immunity critical for iosBio's differentiation.

More companies in United Kingdom →